2011
DOI: 10.1111/j.1369-1600.2011.00319.x
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Environmental stimuli repeatedly associated with the self-administered drugs may acquire motivational importance. Because dopamine (DA) D(2) /D(3) partial agonists and D(3) antagonists interfere with the ability of drug-associated cues to induce drug-seeking behaviour, the present study investigated whether bifeprunox, 7-[4-([1,1'biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone mesylate), a high-affinity partial agonist of the D(2) subfamily of DA receptors and of serotonin(1A) receptors, influence… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
7
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 56 publications
1
7
0
Order By: Relevance
“…The present study also demonstrated that treatment with Bifeprunox significantly decreased locomotor activity, along with centre frequency and duration compared to the control group (Table 1). Although a decrease in locomotion following Bifeprunox treatment has been previously reported [71], this study is the first to demonstrate such effects with a decrease in weight gain. Although the weight loss associated with Bifeprunox treatment might be largely due to a reduced food intake, decreases in centre duration and centre frequency along with the decreases in body weight gain, food and water intake may potentially indicate possible increases in anxiety levels with Bifeprunox drug treatment, although it has previously been found to have potential anti-anxiolytic actions [36,72,73].…”
Section: Discussionsupporting
confidence: 42%
“…The present study also demonstrated that treatment with Bifeprunox significantly decreased locomotor activity, along with centre frequency and duration compared to the control group (Table 1). Although a decrease in locomotion following Bifeprunox treatment has been previously reported [71], this study is the first to demonstrate such effects with a decrease in weight gain. Although the weight loss associated with Bifeprunox treatment might be largely due to a reduced food intake, decreases in centre duration and centre frequency along with the decreases in body weight gain, food and water intake may potentially indicate possible increases in anxiety levels with Bifeprunox drug treatment, although it has previously been found to have potential anti-anxiolytic actions [36,72,73].…”
Section: Discussionsupporting
confidence: 42%
“…Rats were trained in 16 identical operant chambers (ENV‐007, MED Associates Inc., St Albans, VT, USA) as previously described (Di Clemente et al . ; Cervo et al . ).…”
Section: Methodsmentioning
confidence: 99%
“…Rats were then placed under the extinction condition until the end of the experiments where no S D s were presented and the instrumental lever response produced neither the reinforcer nor the CSs (Torregrossa, Sanchez, & Taylor ; Di Clemente et al . ; Cervo et al . ).…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations